Dr. Drilon Discusses CNS Penetration in NSCLC

Alexander Drilon, MD
Published: Thursday, Nov 09, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system (CNS) penetration in the treatment of non-small cell lung cancer (NSCLC).

In general, NSCLC tumors like to metastasize to a CNS compartment, says Drilon. Now that tyrosine kinase inhibitors (TKIs) are being tested, it is important to focus on CNS penetration during new drug development.

Drilon says that investigators could take note from studies in ALK-rearranged disease, which has been testing drugs that successfully penetrate the CNS.
 


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system (CNS) penetration in the treatment of non-small cell lung cancer (NSCLC).

In general, NSCLC tumors like to metastasize to a CNS compartment, says Drilon. Now that tyrosine kinase inhibitors (TKIs) are being tested, it is important to focus on CNS penetration during new drug development.

Drilon says that investigators could take note from studies in ALK-rearranged disease, which has been testing drugs that successfully penetrate the CNS.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x